Prashanth Ravishankar

Dr. Prashanth Ravishankar

Institute for Integrative and Innovative Research, University of Arkansas, Fayetteville, Arkansas, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
JKJ. Pradeep Kumar
J. Pradeep Kumar
LLL. Lakshmi
L. Lakshmi
VJV. Jyothsna
V. Jyothsna
Prashanth RavishankarPrashanth Ravishankar
Prashanth Ravishankar
SSSaravannan Sekaran
Saravannan Sekaran
NSN. Selvamurugan
N. Selvamurugan
The scaffolds for bone tissue engineering should be porous to harbor the growth of new tissue ingrowths, biodegradable with no toxic end products, and biocompatible with no cytotoxicity. In this study we report that Diopside (CaMgSi2O6) (Dp) particles can be synthesized at a more economical route using the agricultural waste rice straw. Along with chitosan (CS) matrix, the CS/Dp scaffolds were synthesized and evaluated for their physico-chemical properties by SEM, EDS, XRD, FT-IR studies. Addition of Dp particles to chitosan matrix decreased water retention capacity but there was no change in their degradation properties. Dp particles in CS/Dp scaffolds exhibited good affinity for protein adsorption. Apatite forming ability of the CS/Dp scaffolds depicted their bioactivity. These scaffolds were found to be compatible with human osteoblastic cells (MG-63) and the cells were able to attach and proliferate with extended morphology on the CS/Dp membranes. The CS/Dp scaffolds supported up regulation of mRNA expression of osteoblast differentiation marker genes such alkaline phosphatase (ALP), type I collagen (COL-I) in the presence of osteogenic environment suggesting their osteo-conductive nature. In vivo rat model system identified that the CS/Dp scaffolds are biocompatible and may have the property of recruiting cells due to deposition of collagen. Hence, these studies suggest that the prepared CS/Dp scaffolds have potential applications towards bone tissue engineering.

26 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ADAnna Daily
Anna Daily
Prashanth RavishankarPrashanth Ravishankar
Prashanth Ravishankar
SHSteve Harms
Steve Harms
VKV. Suzanne Klimberg
V. Suzanne Klimberg
The changing expression levels of ocular proteins in response to systemic disease has been well established in literature. In this study, we examined the ocular proteome to identify protein biomarkers with altered expression levels in women diagnosed with breast cancer. Tear samples were collected from 273 participants using Schirmer strip collection methods. Following protein elution, proteome wide trypsin digestion with Liquid chromatography/tandem mass spectrometry (LC-MS/MS) was used to identify potential protein biomarkers with altered expression levels in breast cancer patients. Selected biomarkers were further validated by enzyme linked immunosorbent assay (ELISA). A total of 102 individual tear samples (51 breast cancer, 51 control) were analyzed by LC-MS/MS which identified 301 proteins. Spectral intensities between the groups were compared and 14 significant proteins (p-value <0.05) were identified as potential biomarkers in breast cancer patients. Three biomarkers, S100A8 (p-value = 0.0069, 7.8-fold increase), S100A9 (p-value = 0.0048, 10.2-fold increase), and Galectin-3 binding protein (p-value = 0.01, 3.0-fold increase) with an increased expression in breast cancer patients were selected for validation using ELISA. Validation by ELISA was conducted using 171 individual tear samples (75 Breast Cancer and 96 Control). Similar to the observed LC-MS/MS results, S100A8 (p-value <0.0001) and S100A9 (p-value <0.0001) showed significantly higher expression in breast cancer patients. However, galectin-3 binding protein had increased expression in the control group. Our results provide further support for using tear proteins to detect non-ocular systemic diseases such as breast cancer. Our work provides crucial details to support the continued evaluation of tear samples in the screening and diagnosis of breast cancer and paves the way for future evaluation of the tear proteome for screening and diagnosis of systemic diseases.

13 May 2021 in Tissue Engineering Part A
Verified
Journal Article
Closed access
Prashanth RavishankarPrashanth Ravishankar
Prashanth Ravishankar
AOAsya Ozkizilcik
Asya Ozkizilcik
AHAnushae Husain
Anushae Husain
KBKartik Balachandran
Kartik Balachandran
This study investigates polymer fiber-reinforced protein-polysaccharide-based hydrogels for heart valve tissue engineering applications. Polycaprolactone and gelatin (3:1) blends were jet-spun to fabricate aligned fibers that possessed fiber diameters in the range found in the native heart valve. These fibers were embedded in methacrylated hydrogels made from gelatin, sodium hyaluronate, and chondroitin sulfate to create fiber-reinforced hydrogel composites (HCs). The fiber-reinforced gelatin glycosaminoglycan (GAG)-based HC possessed interconnected porous structures and porosity higher than fiber-only conditions. These fiber-reinforced HCs exhibited compressive modulus and biaxial mechanical behavior comparable to that of native porcine aortic valves. The fiber-reinforced HCs were able to swell higher and degraded less than the hydrogels. Elution studies revealed that less than 20% of incorporated gelatin methacrylate and GAGs were released over 2 weeks, with a steady-state release after the first day. When cultured with porcine valve interstitial cells (VICs), the fiber-reinforced composites were able to maintain higher cell viability compared with fiber-only samples. Quiescent VICs expressed alpha smooth muscle actin and calponin showing an activated phenotype, along with a few cells expressing the proliferation marker Ki67 and negative expression for RUNX2, an osteogenic marker. Our study demonstrated that compared with the hydrogels and fibers alone, combining both components can yield durable, reinforced composites that mimic heart valve mechanical behavior, while maintaining high cell viability and expressing positive activation as well as proliferation markers.

11 March 2022 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Prashanth RavishankarPrashanth Ravishankar
Prashanth Ravishankar
ADAnna Daily
Anna Daily
The need to easily isolate small molecular weight proteins and genomic fragments has prompted a search for an alternative biofluid to blood that has traversed sweat, urine, saliva, and even breath. In this study, both the genomic and proteomic profiles of tears and blood are evaluated to determine the similarity and differences between the two biofluids. Both fluids were tested utilizing microarray panels for identifying proteins as well as isolation of microRNA for sequencing. As anticipated, most (118) of the proteins detected in plasma were also detected in the tear samples, with tear samples also showing 34 unique proteins that were not found in the plasma. Over 400 microRNAs were isolated in both samples with 250 microRNA fragments commonly expressed in both tears and blood. This preliminary analysis, along with simplicity of collection and processing, lends credence to further investigate tears as an alternative biofluid to blood.

21 September 2016 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Closed access
PDF file
AKAlex Khang
Alex Khang
Prashanth RavishankarPrashanth Ravishankar
Prashanth Ravishankar
AKAditya Krishnaswamy
Aditya Krishnaswamy
PAPatrick K. Anderson
Patrick K. Anderson
SCStephanie Cone
Stephanie Cone
KBKartik Balachandran
Kartik Balachandran

1 January 2023 in Biomarker Insights
Verified
Journal Article
Open access
PDPaola Monterroso Diaz
Paola Monterroso Diaz
ALAshton Leehans
Ashton Leehans
Prashanth RavishankarPrashanth Ravishankar
Prashanth Ravishankar
ADAnna Daily
Anna Daily
Cancer is a complex and heterogeneous disease that poses a significant threat to global health. Early diagnosis and treatment are critical for improving patient outcomes, and the use of liquid biopsies has emerged as a promising approach for cancer detection and monitoring. Traditionally, cancer diagnosis has relied on invasive tissue biopsies, the collection of which can prove challenging for patients and the results of which may not always provide accurate results due to tumor heterogeneity. Liquid biopsies have gained increasing attention as they provide a non-invasive and accessible source of cancer biomarkers, which can be used to diagnose cancer, monitor treatment response, and detect relapse. The integration of -omics technologies, such as proteomics, genomics, and metabolomics, has further enhanced the capabilities of liquid biopsies by introducing precision oncology and enabling the tailoring of treatment for individual patients based on their unique tumor biology. In this review, we will discuss the challenges and advances in the field of cancer liquid biopsies and the integration of -omics technologies for different types of liquid biopsies, including blood, tear, urine, sweat, saliva, and cerebrospinal fluid.